58092-8
Acylcarnitine newborn screen panel
Active
Term Description
Newborn screening dried blood spot analysis by tandem mass spectrometry (MS/MS) requires pre-processing the specimen with one of two alternative reagent methods referred to as derivatized and non-derivatized (or underivatized) methods. The methods are similar and nearly all analytes and ratios are identical with the limited number of exceptions noted in the description of the LOINC codes. Some labs choose to use the non-derivatized method because it may be faster or less expensive for their operations. There are no analytes which would be interpreted differently based on the method used to process the specimen so there is no need for different LOINC codes for the same compounds based on the reagents. In a few cases, a different LOINC code is used for the derivatized or non-derivatized tandem mass spectrometry (MS/MS) method because based on the reagents used in processing, different analytes are measured or different sets of analytes become isobaric, which means that they cannot be distinguished on the MS/MS because they have the same molecular weight after reagent processing.
Source: Regenstrief LOINC
Panel Hierarchy
Details for each LOINC in Panel LHC-Forms
LOINC | Name | R/O/C | Cardinality | Example UCUM Units |
---|---|---|---|---|
58092-8 | Acylcarnitine newborn screen panel | C | ||
Indent58088-6 | Acylcarnitine newborn screen interpretation | C | ||
Indent58093-6 | Acylcarnitine newborn screening comment-discussion | C | ||
Indent57084-6 | Fatty acid oxidation newborn screen panel | C | ||
Indent Indent46736-5 | Fatty acid oxidation defects newborn screen interpretation | C | ||
Indent Indent57792-4 | Fatty acid oxidation conditions suspected [Identifier] in DBS | C | ||
Indent Indent57709-8 | Fatty acid oxidation defects newborn screening comment-discussion | C | ||
Indent Indent38481-8 | Carnitine free (C0) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53233-3 | Carnitine free (C0)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53234-1 | Carnitine free (C0)/Stearoylcarnitine (C18) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53235-8 | Carnitine free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53236-6 | Carnitine.free (C0)+Acetylcarnitine (C2)+Propionylcarnitine (C3)+Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)+Stearoylcarnitine (C18)/Citrulline [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent75211-3 | Propionylcarnitine (C3)+Palmitoylcarnitine (C16) [Moles/volume] in DBS | C | umol/L | |
Indent Indent75212-1 | Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {ratio} | |
Indent Indent54462-7 | Malonylcarnitine (C3-DC) [Moles/volume] in DBS | C | umol/L | |
Indent Indent75213-9 | Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {ratio} | |
Indent Indent50157-7 | Acetylcarnitine (C2) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53166-5 | Butyrylcarnitine+Isobutyrylcarnitine (C4) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53167-3 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53168-1 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Propionylcarnitine (C3) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53169-9 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent50102-3 | 3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent45211-0 | Hexanoylcarnitine (C6) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53173-1 | 3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent45207-8 | Glutarylcarnitine (C5-DC) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53174-9 | Octenoylcarnitine (C8:1) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53175-6 | Octanoylcarnitine (C8) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53176-4 | Octanoylcarnitine (C8)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53177-2 | Octanoylcarnitine (C8)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53178-0 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53402-4 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53179-8 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53180-6 | Decadienoylcarnitine (C10:2) [Moles/volume] in DBS | C | umol/L | |
Indent Indent45198-9 | Decenoylcarnitine (C10:1) [Moles/volume] in DBS | C | umol/L | |
Indent Indent45197-1 | Decanoylcarnitine (C10) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53182-2 | 3-Hydroxydecenoylcarnitine (C10:1-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53183-0 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53403-2 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53184-8 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53185-5 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53186-3 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent45200-3 | Dodecenoylcarnitine (C12:1) [Moles/volume] in DBS | C | umol/L | |
Indent Indent45199-7 | Dodecanoylcarnitine (C12) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53188-9 | 3-Hydroxydodecenoylcarnitine (C12:1-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53189-7 | 3-Hydroxydodecanoylcarnitine (C12-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53190-5 | Tetradecadienoylcarnitine (C14:2) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53191-3 | Tetradecenoylcarnitine (C14:1) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53192-1 | Tetradecanoylcarnitine (C14) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53193-9 | Tetradecenoylcarnitine (C14:1)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53194-7 | Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53195-4 | Tetradecenoylcarnitine (C14:1)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent70159-9 | Tetradecenoylcarnitine (C14:1)/Tetradecanoylcarnitine (C14) [Molar ratio] in DBS | C | {ratio} | |
Indent Indent53196-2 | 3-Hydroxytetradecadienoylcarnitine (C14:2-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53197-0 | 3-Hydroxytetradecenoylcarnitine (C14:1-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent50281-5 | 3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53198-8 | Palmitoleylcarnitine (C16:1) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53199-6 | Palmitoylcarnitine (C16) [Moles/volume] in DBS | C | umol/L | |
Indent Indent50121-3 | 3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent50125-4 | 3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53201-0 | 3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent45217-7 | Linoleoylcarnitine (C18:2) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53202-8 | Oleoylcarnitine (C18:1) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53241-6 | Stearoylcarnitine (C18) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53400-8 | Stearoylcarnitine (C18)/Propionylcarnitine (C3) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent50109-8 | 3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent50113-0 | 3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent50132-0 | 3-Hydroxystearoylcarnitine (C18-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53836-3 | ABCD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method | |||
Indent57085-3 | Organic acid newborn screen panel | C | ||
Indent Indent46744-9 | Organic acidemias newborn screen interpretation | C | ||
Indent Indent57791-6 | Organic acidemia conditions suspected [Identifier] in DBS | C | ||
Indent Indent57708-0 | Organic acidemias defects newborn screening comment-discussion | C | ||
Indent Indent50157-7 | Acetylcarnitine (C2) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53237-4 | Acrylylcarnitine (C3:1) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53160-8 | Propionylcarnitine (C3) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53161-6 | Propionylcarnitine (C3)/Methionine [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53162-4 | Propionylcarnitine (C3)/Carnitine.free (C0) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53163-2 | Propionylcarnitine (C3)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent54462-7 | Malonylcarnitine (C3-DC) [Moles/volume] in DBS | C | umol/L | |
Indent Indent67708-8 | Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent75213-9 | Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {ratio} | |
Indent Indent53164-0 | Propionylcarnitine (C3)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53166-5 | Butyrylcarnitine+Isobutyrylcarnitine (C4) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53167-3 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53168-1 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Propionylcarnitine (C3) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53169-9 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53170-7 | Tiglylcarnitine (C5:1) [Moles/volume] in DBS | C | umol/L | |
Indent Indent45207-8 | Glutarylcarnitine (C5-DC) [Moles/volume] in DBS | C | umol/L | |
Indent Indent75216-2 | Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in DBS | {ratio} | ||
Indent Indent67701-3 | Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent67710-4 | Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent67711-2 | Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent45216-9 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53238-2 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Carnitine.free (C0) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53239-0 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53240-8 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53401-6 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent50106-4 | 3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53171-5 | 3-Hydroxyisovalerylcarnitine (C5-OH)/Carnitine.free (C0) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53172-3 | 3-Hydroxyisovalerylcarnitine (C5-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53178-0 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53402-4 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53179-8 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent45222-7 | Methylmalonylcarnitine (C4-DC) [Moles/volume] in DBS | C | umol/L | |
Indent Indent67709-6 | Methylmalonylcarnitine (C4-DC)+3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53181-4 | Methylmalonylcarnitine (C4-DC)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53183-0 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53403-2 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53184-8 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53185-5 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53186-3 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
Indent Indent53187-1 | Methylglutarylcarnitine (C6-DC) [Moles/volume] in DBS | C | umol/L | |
Indent Indent53165-7 | Formiminoglutamate [Moles/volume] in DBS | C | umol/L |
Fully-Specified Name
- Component
- Acylcarnitine newborn screen panel
- Property
- -
- Time
- Pt
- System
- Bld.dot
- Scale
- -
- Method
Additional Names
- Short Name
- Acylcarnitine NBS pnl DBS
- Display Name
- Acylcarnitine NBS panel (DBS)
- Consumer Name Alpha Get Info
- Acylcarnitine NBS Panel, Dried blood spot
Basic Attributes
- Class
- PANEL.CHEM
- Type
- Laboratory
- First Released
- Version 2.29
- Last Updated
- Version 2.77
- Order vs. Observation
- Order
- Common Test Rank Get Info
- 16130
- Panel Type
- Panel
Member of these Panels
LOINC | Long Common Name |
---|---|
104191-2 | Guanidinoacetate methyltransferase (GAMT) deficiency newborn screening panel |
54089-8 | Newborn screening panel American Health Information Community (AHIC) |
Language Variants Get Info
Tag | Language | Translation |
---|---|---|
es-ES | Spanish (Spain) | Panel de cribado neonatal de acilcarnitina: |
es-MX | Spanish (Mexico) | Panel de pantalla para recién nacidos de acilcarnitina: |
et-EE | Estonian (Estonia) | Atsüülkarnitiini sõeluuring vastsündinul: Synonyms: Juhuslik Veri |
fr-FR | French (France) | Acylcarnitine dépistage néonatal panel: |
fr-BE | French (Belgium) | Panel screening néonatal acylcarnitine: |
it-IT | Italian (Italy) | Acilcarnitina, panel screening neonatale: Synonyms: Chimica Panel screening neonatale acilcarnitina Punto nel tempo (episodio) Sangue Set di prescrizione chimica Spot sangue secco |
nl-NL | Dutch (Netherlands) | acylcarnitine pasgeborene screening panel: |
pt-BR | Portuguese (Brazil) | Acilcarnitina triagem neonatal painel: Synonyms: ; |
ru-RU | Russian (Russian Federation) | Ацилкарнитин новорождённый скрин панель: Synonyms: Кровь Кровь сухая капля Точка во времени; |
zh-CN | Chinese (China) | 酰基肉碱新生儿筛查组套: Synonyms: 全血斑点(滤纸); |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=58092-8 - Questionnaire definition
- https:
//fhir.loinc.org/Questionnaire/?url=http: //loinc.org/q/58092-8
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright